Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents

Patent metadata

Field	Value
Publication number	US-12312293-B2
Application number	US-202318164136-A
Country	US
Kind code	B2
Filing date	Feb 3, 2023
Priority date	Sep 19, 2019
Publication date	May 27, 2025
Grant date	May 27, 2025

Abstract

The disclosure features novel lipids and compositions involving the same. Lipid nanoparticles (e.g., empty LNPs or loaded LNPs) include a novel lipid as well as additional lipids such as phospholipids, structural lipids, and PEG lipids. Lipid nanoparticles (e.g., empty LNPs or loaded LNPs) further including therapeutic and/or prophylactics such as RNA are useful in the delivery of therapeutic and/or prophylactics to mammalian cells or organs to, for example, regulate polypeptide, protein, or gene expression.

First claim

The invention claimed is:

1. A compound of Formula (A-a):

or its N-oxide, or a salt or isomer thereof, wherein:
R αβ , R αγ and R αδ are each independently selected from the group consisting of H, C 2-12 alkyl, and C 2-12 alkenyl, wherein at least one of R αβ , R αγ , and R αδ is selected from the group consisting of C 2-12 alkyl and C 2-12 alkenyl;
R 4 is selected from the group consisting of —(CH 2 ) 2 OH, —(CH 2 ) 3 OH, —(CH 2 ) 4 OH, and —(CH 2 ) 5 OH;
M and M′ are each independently selected from the group consisting of —C(O)O— and —OC(O)—; and
R′ is a C 1-12 alkyl or C 2-12 alkenyl.

2. A compound of Formula (A-a2):

or its N-oxide, or a salt or isomer thereof, wherein R αβ and R αδ are each independently selected from the group consisting of H, C 2-12 alkyl, and C 2-12 alkenyl; and R αγ is a C 2 alkyl, C 3 alkyl, C 4 alkyl, C 5 alkyl, or C 6 alkyl;
R 4 is —(CH 2 ) 2 OH or

wherein
R 10 is N(R) 2 ; each R is independently selected from the group consisting of C 1-6 alkyl, C 2-3 alkenyl, and H; and n2 is selected from the group consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10;
M and M′ are each independently selected from the group consisting of —C(O)O— and —OC(O)—; and
R′ is a C 1-12 alkyl or C 2-12 alkenyl.

3. The compound of claim 1 , wherein R 4 is —(CH 2 ) 2 OH.

4. The compound of claim 1 , wherein M′ and M are each —C(O)O—.

5. The compound of claim 1 , wherein R′ is a C 3 or C 4 alkyl.

6. The compound of claim 1 , wherein R αγ is a C 2-6 alkyl and R′ is a C 3 alkyl.

7. The compound of claim 1 , wherein R αβ and R αδ are each H.

8. The compound of claim 1 , wherein R αγ is a C 2 -alkyl, C 3 -alkyl, or a C 4 alkyl.

9. An empty lipid nanoparticle (empty LNP) comprising a compound of claim 1 , a phospholipid, a structural lipid, and a PEG lipid.

10. The empty LNP of claim 9 , comprising about 40 mol % to about 60 mol % said compound, about 0 mol % to about 20 mol % phospholipid, about 30 mol % to about 50 mol % structural lipid, and about 0 mol % to about 5 mol % PEG lipid.

11. The empty LNP of claim 9 , wherein:
(i) the phospholipid is selected from the group consisting of:
1,2-dilinoleoyl-sn-glycero-3-phosphocholine (DLPC),
1,2-dimyristoyl-sn-glycero-phosphocholine (DMPC),
1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC),
1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC),
1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC),
1,2-diundecanoyl-sn-glycero-phosphocholine (DUPC),
1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC),
1,2-di-O-octadecenyl-sn-glycero-3-phosphocholine (18:0 Diether PC),
1-oleoyl-2-cholesterylhemisuccinoyl-sn-glycero-3-phosphocholine (OChemsPC),
1-hexadecyl-sn-glycero-3-phosphocholine (C16 Lyso PC),
1,2-dilinolenoyl-sn-glycero-3-phosphocholine,
1,2-diarachidonoyl-sn-glycero-3-phosphocholine,
1,2-didocosahexaenoyl-sn-glycero-3-phosphocholine, 1,2-dioleoyl-sn-glycero-3-p hosphoethanolamine (DOPE),
1,2-diphytanoyl-sn-glycero-3-phosphoethanolamine (ME 16.0 PE),
1,2-distearoyl-sn-glycero-3-phosphoethanolamine,
1,2-dilinoleoyl-sn-glycero-3-phosphoethanolamine,
1,2-dilinolenoyl-sn-glycero-3-phosphoethanolamine,
1,2-diarachidonoyl-sn-glycero-3-phosphoethanolamine,
1,2-didocosahexaenoyl-sn-glycero-3-phosphoethanolamine,
1,2-dioleoyl-sn-glycero-3-phospho-rac-(1-glycerol) sodium salt (DOPG), sphingomyelin, and mixtures thereof,

(ii) the structural lipid is selected from the group consisting of cholesterol, fecosterol, sitosterol, ergosterol, campesterol, stigmasterol, brassicasterol, and mixtures thereof;
(iii) the PEG lipid is selected from the group consisting of a PEG-modified phosphatidylethanolamine, a PEG-modified phosphatidic acid, a PE(G-modified ceramide, a PEG-modified dialkylamine, a PEG-modified diacylglycerol, a PEG-modified dialkylglycerol, and mixtures thereof; and/or
(iv) the PEG lipid is selected from PEG2k-DMG and PEG-1:

and mixtures thereof.

12. A loaded lipid nanoparticle (loaded LNP), which comprises the empty LNP of claim 9 , and one or more therapeutic and/or prophylactic agents.

13. The loaded LNP of claim 12 , wherein the one or more therapeutic and/or prophylactic agents is a nucleic acid.

14. The loaded LNP of claim 12 , wherein the RNA is an mRNA.

15. A pharmaceutical composition comprising the loaded LNP of claim 12 and a pharmaceutically acceptable carrier.

16. A method of delivering a therapeutic and/or prophylactic agent to a cell within a subject, the method comprising administering to the subject the loaded LNP of claim 12 .

17. A method of specifically delivering a therapeutic and/or prophylactic agent to an organ of a subject, the method comprising administering to the subject the loaded LNP of claim 12 .

18. A method of producing a polypeptide of interest in a cell within a subject, the method comprising administering to the subject the loaded LNP of claim 12 .

19. A method of treating a disease or disorder in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the loaded LNP of claim 12 .

20. The method of claim 17 , wherein:
(i) the organ is selected from the group consisting of liver, kidney, lung, and spleen; and/or
(ii) the administering is performed parenterally, intramuscularly, intradermally, subcutaneously, and/or intravenously.

Assignees

• Modernatx Inc

Inventors

• Benenato Kerry E
• Cornebise Mark
• Hennessy Edward
• Kumarasinghe Ellalahewage S

Classifications

• A61K48/005

  characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered · CPC title

• A61K48/0033

  the non-active part being non-polymeric · CPC title

• A61K31/713

  Double-stranded nucleic acids or oligonucleotides · CPC title

• A61K9/1272 Primary

  comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers (lipids as modifying agents {A61K47/543}) · CPC title

• A61K47/543

  Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine · CPC title